secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-047670
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm FY2025 total rev $146M; XPOVIO $115M; net loss $196M; FY2026 guidance $130-150M; key trial readouts in 2026
--------------------------------------------------------------------------------

- FY2025 total revenue $146.1M (up from $145.2M); U.S. XPOVIO net product revenue $114.9M (up from $112.8M).
- FY2025 net loss $196.0M ($17.93/share) vs $76.4M prior year, driven by $62.4M loss on debt extinguishment.
- Cash, cash equivalents and investments $64.1M at Dec 31, 2025 vs $109.1M at Dec 31, 2024; runway into Q2 2026.
- FY2026 guidance: total revenue $130-150M, XPOVIO net product $115-130M, R&D+SG&A $230-245M.
- Phase 3 SENTRY myelofibrosis trial top-line data expected March 2026; Phase 3 endometrial cancer data mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/0001193125-26-047670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/kpti-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-047670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer